Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, representing a 10.5% increase compared to the prior year. Driven by strong procedure volumes and robust performance across its businesses, the company raised its full-year 2026 sales growth and adjusted EPS guidance.
Q3 sales grew 10.5% to $1.72 billion, with constant currency sales up 11.2%.
Q3 EPS was $0.53, while adjusted EPS reached $0.80, up 19% versus the prior year.
Full-year 2026 sales growth guidance was increased to approximately 11.5% from the previous 10% to 11% range.
Adjusted EPS guidance for 2026 was raised to a range of $2.97 to $3.05.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Edwards Lifesciences's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$6.07B
+11.5%
$1.83
-73.7%
17.7%
FY2024
$5.44B
+8.6%
$6.97
+203.0%
76.7%
FY2023
$5.01B
+12.2%
$2.30
-5.7%
28.0%
FY2022
$4.46B
-14.7%
$2.44
+2.5%
34.1%
FY2021
$5.23B
+19.3%
$2.38
+83.1%
28.7%
Frequently asked questions
When is Edwards Lifesciences's next earnings date?
Edwards Lifesciences has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Edwards Lifesciences earn last quarter?
For the quarter ended Sep 2026, Edwards Lifesciences reported diluted EPS of $0.53 (+6.0% year over year) on revenue of $1.72B (+10.5%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.